In this issue:
- Combination subcutaneous cagrilintide + semaglutide for type 2 diabetes
- Oral semaglutide for overweight/obesity
- Oral semaglutide for type 2 diabetes
- Potent glucose-lowering effect with low-dose sulfonylurea + DPP-4 inhibitor
- Identifying diabetes-related dementia in NZ
- Late meal intake associated with abdominal obesity and metabolic disorders
- Fully closed-loop automated insulin delivery for type 2 diabetes
- Diabetes self-management: young vs. usual age-onset
- Causes of death among Australians with type 1 or 2 diabetes
- Type 2 diabetes remission determinants after short-term insulin
Please login below to download this issue (PDF)